NCT05094336 2026-01-30
MTAPESTRY 101
Amgen
Phase 1/2 Active not recruiting
Clinical Trials
7 trialsNCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT03505320 2025-10-20
ILUSTRO
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT03421288 2025-07-25
DANTE
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT01924819 2025-03-04
TOPGEAR
Australasian Gastro-Intestinal Trials Group
Phase 2/3 Active not recruiting
NCT04745988 2024-11-15
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT02931890 2024-05-02
CRITICS-II
The Netherlands Cancer Institute
Phase 2 Active not recruiting